Chargement en cours...
The “C3aR Antagonist” SB290157 is a Partial C5aR2 Agonist
Innate immune complement activation generates the C3 and C5 protein cleavage products C3a and C5a, defined classically as anaphylatoxins. C3a activates C3aR, while C5a activates two receptors (C5aR1 and C5aR2) to exert their immunomodulatory activities. The non-peptide compound, SB290157, was origin...
Enregistré dans:
| Publié dans: | Front Pharmacol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2021
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7859635/ https://ncbi.nlm.nih.gov/pubmed/33551801 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.591398 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|